Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The urologic literature suggests that there is an association between a variety of
psychiatric disorders and incontinence. Most notably, depression is found in a significant
percentage of patients with urinary incontinence. Depression also occurs in other conditions
associated with urinary urge incontinence, such as aging and dementia, and in neurologic
disorders such as normal pressure hydrocephalus. Correction of some neurologic disorders
eliminates both depression and urge incontinence. Although chronic medical disorders such as
urge incontinence may lead to depression, an alternative hypothesis is that these two
conditions share a common neurochemical pathogenesis. Lowering monoamines such as serotonin
and noradrenaline in the central nervous system (CNS) leads to depression and urinary
frequency and a hyperactive bladder in experimental animals. Thus, depression may not only be
the result of persistent urinary incontinence, but individuals with altered CNS monoamines
could manifest both depression and an overactive bladder. The latter condition may lead to
urge incontinence, urinary frequency, urgency, or enuresis. Uncovering further evidence for
such a linkage could serve as the basis for the development of genetic markers and novel
therapeutic interventions for these two conditions.
In this study, the investigators will evaluate the efficacy and safety of SSRI on OAB
patients who does not respond to the antimuscarinic agents.